BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27358897)

  • 1. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.
    Agarwal A; Morrone K; Bartenstein M; Zhao ZJ; Verma A; Goel S
    Stem Cell Investig; 2016; 3():5. PubMed ID: 27358897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ALK5 inhibition in myelofibrosis.
    Yue L; Bartenstein M; Zhao W; Ho WT; Han Y; Murdun C; Mailloux AW; Zhang L; Wang X; Budhathoki A; Pradhan K; Rapaport F; Wang H; Shao Z; Ren X; Steidl U; Levine RL; Zhao ZJ; Verma A; Epling-Burnette PK
    JCI Insight; 2017 Apr; 2(7):e90932. PubMed ID: 28405618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in understanding myelofibrosis and essential thrombocythemia.
    Vainchenker W; Constantinescu SN; Plo I
    F1000Res; 2016; 5():. PubMed ID: 27134742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.
    Gastinne T; Vigant F; Lavenu-Bombled C; Wagner-Ballon O; Tulliez M; Chagraoui H; Villeval JL; Lacout C; Perricaudet M; Vainchenker W; Benihoud K; Giraudier S
    Exp Hematol; 2007 Jan; 35(1):64-74. PubMed ID: 17198875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis.
    Vannucchi AM; Bianchi L; Paoletti F; Pancrazzi A; Torre E; Nishikawa M; Zingariello M; Di Baldassarre A; Rana RA; Lorenzini R; Alfani E; Migliaccio G; Migliaccio AR
    Blood; 2005 May; 105(9):3493-501. PubMed ID: 15665119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
    Alshemmari SH; Rajan R; Emadi A
    Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.
    Chagraoui H; Komura E; Tulliez M; Giraudier S; Vainchenker W; Wendling F
    Blood; 2002 Nov; 100(10):3495-503. PubMed ID: 12393681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor β- and interleukin 13-producing mast cells are associated with fibrosis in bone marrow.
    Nakayama S; Yokote T; Hiraoka N; Akioka T; Nishiwaki U; Miyoshi T; Iwaki K; Fumimoto A; Masuda Y; Hatooka J; Fujimoto M; Nishimura Y; Tsuji M
    Hum Pathol; 2017 Apr; 62():180-186. PubMed ID: 28159675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canonical Wnt/β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis.
    Lucijanic M; Livun A; Tomasovic-Loncaric C; Stoos-Veic T; Pejsa V; Jaksic O; Prka Z; Kusec R
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):523-526. PubMed ID: 27381374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis.
    Ciaffoni F; Cassella E; Varricchio L; Massa M; Barosi G; Migliaccio AR
    Blood Cells Mol Dis; 2015 Mar; 54(3):234-41. PubMed ID: 25703685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms.
    Chatain N; Koschmieder S; Jost E
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32806517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
    Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor β-mediated micromechanics modulates disease progression in primary myelofibrosis.
    Teodorescu P; Pasca S; Jurj A; Gafencu G; Joelsson JP; Selicean S; Moldovan C; Munteanu R; Onaciu A; Tigu AB; Buse M; Zimta AA; Stiufiuc R; Petrushev B; Desmirean M; Dima D; Vlad C; Bergthorsson JT; Berce C; Ciurea S; Ghiaur G; Tomuleasa C
    J Cell Mol Med; 2020 Oct; 24(19):11100-11110. PubMed ID: 32889753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myeloproliferative neoplasms - Update on diagnosis and treatment].
    Meyer SC; Drexler B; Skoda RC
    Ther Umsch; 2019; 76(9):487-495. PubMed ID: 32157965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.